Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma - Wikidata - awgldk - TriplyDB

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

http://www.wikidata.org/entity/Q33216260

about

A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects.Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.Intravesical treatments of bladder cancer: review.Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients Emerging intravesical therapies for management of nonmuscle invasive bladder cancer Investigational therapies for non-muscle invasive bladder cancer.

P2860

Q26739665-FA979AD7-1F7E-43AE-8DF0-5D3FC4C3ABF6 Q33940289-C7CD029F-706D-4EA7-AA54-5B356F1071FD Q34293651-34C51E64-088C-4B73-9CB9-237B6AC6AE66 Q36508627-921D4DD6-AB9E-4C36-B3B1-991C2075F29F Q36738254-1F209595-95EF-4D13-8A75-726BB0AC7643 Q37018478-8B4407BC-39DD-4772-90AB-0C791654A0E5 Q37283563-BE572F48-3B66-4976-9E44-491783D320C7 Q37676223-F3DAB7E6-9289-4737-B960-79A0E4EC6208

P2860

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

http://www.wikidata.org/entity/Q33216260

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase I trial of intravesical ...... itional cell bladder carcinoma

@ast

Phase I trial of intravesical ...... itional cell bladder carcinoma

@en

type

label

Phase I trial of intravesical ...... itional cell bladder carcinoma

@ast

Phase I trial of intravesical ...... itional cell bladder carcinoma

@en

prefLabel

Phase I trial of intravesical ...... itional cell bladder carcinoma

@ast

Phase I trial of intravesical ...... itional cell bladder carcinoma

@en

P1433

Q33216260-29C891BA-A1FD-48B3-AEF5-D3E8097AC37B

P1476

Q33216260-A947B030-E34C-48F9-ACB3-BEF16BE17A4B

P2093

Q33216260-4700C5C6-F034-4E66-9836-0CC82682C8AB

Q33216260-51A7BE58-EBA3-4279-85A9-C9B6EA245367

Q33216260-538A7E79-BDB6-4237-87E7-489F38C7E838

Q33216260-95CF9296-22AE-4B61-8A9D-B8F6771045F4

Q33216260-B7D4C17F-E0A6-46B4-A576-808F0EE48D60

Q33216260-CE45459B-BA97-4AC0-8C52-B7E234ACA78E

Q33216260-F56CD0DF-7D90-4C4B-83A3-94DC9BC8F196

Q33216260-F6BCC0C6-7F01-4D34-9E86-CFEB1E33E048

Q33216260-FB69C89F-3E00-49B9-BFEB-344BF7C8843F

P2860

Q33216260-04BC409C-53CE-45BF-80FE-E6223C290D47

Q33216260-0AE7BEBB-EA04-478E-BD00-E9F6FED8F09E

Q33216260-2DD95FD1-AA18-428C-A7F1-7D9000776022

Q33216260-39381259-C39E-45EF-AE60-4C5D26AD7F63

Q33216260-4913D4E9-F183-4FB2-B52A-9772D6BD6E8B

Q33216260-4E4076E4-A0ED-401D-8B3A-1BFF978D7527

Q33216260-5248758A-89C5-4399-B548-E6C55180C18E

Q33216260-55E70809-272A-4A1D-85DF-615E4C7BE1C8

Q33216260-576EB45F-F18C-4D8B-8335-EE3FFE577557

Q33216260-58C04D69-8CFC-460D-9F2E-6591065F3392

P2888

Q33216260-DB8BA7A2-D03B-4FB7-AF03-64F30B569C6F

P304

Q33216260-7D2F8012-B974-4CBA-BA46-3B45CADB38F5

P31

Q33216260-5517F5D0-F32A-436D-B1C3-35FF504FBE56

P356

Q33216260-90B32F47-7DD6-4271-B903-3A52BBB63AC1

P407

Q33216260-F394C063-8D27-4A87-8C14-4583C7F89F31

P433

Q33216260-C1615077-32EF-407A-B476-892A7A8B30A6

P478

Q33216260-24C575B6-8E38-4413-B24C-7D8A6BB9E6FA

P50

Q33216260-2471DA2A-612A-4F48-867D-0B4F04D49420

Q33216260-B71ED1E6-489C-4E0A-A2F7-935C2184815B

P577

Q33216260-3C3A633E-4187-44ED-AB4A-F3DE02497927

P5875

Q33216260-8013D7DA-FE11-43A1-BE5A-7C497DA903D0

P6179

Q33216260-5A301ED2-F703-4C78-87FD-C48F998562FA

P698

Q33216260-0D2AF820-D3BD-4444-9A86-02FBA5200083

P921

Q33216260-861DC649-F64F-4F74-903D-1D43F0D7E288

P932

Q33216260-3AC23980-F08A-4029-A121-BFEFCC0DDD88

P356

P1433

British Journal of Cancer

P1476

Phase I trial of intravesical ...... itional cell bladder carcinoma

@en

P2093

Cranston D

http://www.w3.org/2001/XMLSchema#string

Crew J

http://www.w3.org/2001/XMLSchema#string

Joel SP

http://www.w3.org/2001/XMLSchema#string

Jones A

http://www.w3.org/2001/XMLSchema#string

Le Monnier K

http://www.w3.org/2001/XMLSchema#string

Ord JJ

http://www.w3.org/2001/XMLSchema#string

Roberts IS

http://www.w3.org/2001/XMLSchema#string

Rogers MA

http://www.w3.org/2001/XMLSchema#string

Streeter E

http://www.w3.org/2001/XMLSchema#string

P2860

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion

Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility.

Oligoclonality in bladder cancer: the implication for molecular therapies.

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.

Suramin: with special reference to onchocerciasis.

A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.

Acute renal toxicity associated with suramin in the treatment of prostate cancer.

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation.

Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.

P2888

P304

2140-2147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602650

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

Rosamonde Elizabeth Banks

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7812786

http://www.w3.org/2001/XMLSchema#string

P6179

1028998867

http://www.w3.org/2001/XMLSchema#string

P698

15928663

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2361814

http://www.w3.org/2001/XMLSchema#string